Botulinum Neurotoxin Type A for the Treatment of Benign Prostatic Hyperplasia: Randomized Study Comparing Two Doses

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author ARNOUK, Rene
BELLUCCI, Carlos Henrique Suzuki
STULL, Roberto Benatuil
BESSA JUNIOR, Jose de
MALAVE, Cesar Augusto
GOMES, Cristiano Mendes FMUSP-HC
dc.date.issued 2012
dc.identifier.citation SCIENTIFIC WORLD JOURNAL, article ID 463574, 6p, 2012
dc.identifier.issn 1537-744X
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/1379
dc.description.abstract Purpose. To assess the efficacy and safety of intraprostatic injection of two botulinum neurotoxin type A (BoNT-A) doses for the treatment of benign prostatic hyperplasia (BPH). Materials and Methods. Men with symptomatic BPH who failed medical treatment were randomized to receive 100 U or 200 U of BoNT-A into the prostate. The International Prostatic Symptom Score (IPSS), maximum flow rate (Q(max)), post-void residual volume (PVR), PSA levels and prostate volume before injection and after 3 and 6 months were evaluated. Adverse events were compared between the groups. Results. Thirty four patients were evaluated, including 17 in the BoNT-A 100 U group and 17 in the BoNT-A 200 U group. Baseline characteristics were similar in both groups. Both doses produced significant improvements in IPSS, Q(max) and PVR after 3 and 6 months and both doses promoted comparable effects. Prostate volume was affected by 200 U BoNT-A injection only after 6 months of treatment. PSA levels were significantly affected in the 100 U group only after 6 months of treatment. In the 200 U group, PSA levels were significantly decreased after 3 and 6 months. The complication rate was similar in both groups. Conclusions. Efficacy and safety of both BoNT-A doses are similar for BPH treatment in the short term followup.
dc.language.iso eng
dc.publisher HINDAWI PUBLISHING CORPORATION
dc.relation.ispartof Scientific World Journal
dc.rights openAccess
dc.subject.other toxin type-a; urinary-tract symptoms; long-term; injection; finasteride; dyssynergia; retention; therapy; relief; men
dc.title Botulinum Neurotoxin Type A for the Treatment of Benign Prostatic Hyperplasia: Randomized Study Comparing Two Doses
dc.type article
dc.rights.holder Copyright HINDAWI PUBLISHING CORPORATION
dc.description.group LIM/55
dc.identifier.doi 10.1100/2012/463574
dc.identifier.pmid 22997495
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author GOMES, Cristiano Mendes:HC:IOT
hcfmusp.author.external · ARNOUK, Rene:Dr Carlos Arvelo Mil Hosp, Dept Urol, Caracas 1060, Miranda, Venezuela
· BELLUCCI, Carlos Henrique Suzuki:Uroclin Joinville, BR-89201700 Joinville, SC, Brazil
· STULL, Roberto Benatuil:Dr Carlos Arvelo Mil Hosp, Dept Urol, Caracas 1060, Miranda, Venezuela
· BESSA JUNIOR, Jose de:Univ Estadual Feira de Santana, Div Urol, BR-44031460 Feira De Santana, BA, Brazil
· MALAVE, Cesar Augusto:Dr Carlos Arvelo Mil Hosp, Dept Urol, Caracas 1060, Miranda, Venezuela
hcfmusp.origem.id WOS:000308605900001
hcfmusp.origem.id 2-s2.0-84867806302
hcfmusp.publisher.city NEW YORK
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Apostolidis A, 2005, J UROLOGY, V174, P977, DOI 10.1097/01.ju.0000169481.42259.54
· Barry MJ, 2001, BRIT MED J, V323, P1042
· Brisinda G, 2009, UROLOGY, V73, P90, DOI 10.1016/j.urology.2008.08.475
· Chuang YC, 2006, J UROLOGY, V175, P1158, DOI 10.1016/S0022-5347(05)00318-6
· Chuang YC, 2006, BJU INT, V98, P1033, DOI 10.1111/j.1464-410X.2006.06479.x
· Chuang YC, 2005, UROLOGY, V66, P775, DOI 10.1016/j.urology.2005.04.029
· Chuang Yao-Chi, 2006, BMC Urol, V6, P12, DOI 10.1186/1471-2490-6-12
· Clifford GM, 2000, EUR UROL, V38, P2, DOI 10.1159/000020246
· de Miguel F, 2006, Actas Urol Esp, V30, P310
· de la Rosette JJMCH, 2001, EUR UROL, V40, P256, DOI 10.1159/000049784
· Doggweiler R, 1998, PROSTATE, V37, P44, DOI 10.1002/(SICI)1097-0045(19980915)37:1<44::AID-PROS7>3.0.CO;2-8
· DYKSTRA DD, 1988, J UROLOGY, V139, P919
· Kuo HC, 2005, UROLOGY, V65, P670, DOI 10.1016/j.urology.2004.10.077
· Lepor H, 1996, NEW ENGL J MED, V335, P533, DOI 10.1056/NEJM199608223350801
· Lim SK, 2008, EUR UROL, V53, P620, DOI 10.1016/j.eururo.2007.10.001
· LUYAO GL, 1994, UROLOGY, V44, P692, DOI 10.1016/S0090-4295(94)80208-4
· MACKENZIE I, 1982, NEUROSCIENCE, V7, P997, DOI 10.1016/0306-4522(82)90056-2
· Maria G, 2003, UROLOGY, V62, P259, DOI 10.1016/S0090-4295(03)00477-1
· McConnell J. D., 1994, TREATING TOBACCO USE, P1
· McConnell JD, 1998, NEW ENGL J MED, V338, P557, DOI 10.1056/NEJM199802263380901
· Narayan P, 2001, UROLOGY, V57, P466, DOI 10.1016/S0090-4295(00)01042-6
· Nasu K, 1996, BRIT J PHARMACOL, V119, P797
· OESTERLING JE, 1995, NEW ENGL J MED, V332, P99
· Park DS, 2006, YONSEI MED J, V47, P706
· Schurch B, 2000, J UROLOGY, V164, P692, DOI 10.1016/S0022-5347(05)67283-7
· Schurch B, 2005, J UROLOGY, V174, P196, DOI 10.1097/01.ju.0000462035.73977.1c
· Silva J, 2008, EUR UROL, V53, P153, DOI 10.1016/j.eururo.2007.08.050
· SIMPSON LL, 1980, J PHARMACOL EXP THER, V212, P16
dc.description.index MEDLINE
hcfmusp.citation.scopus 11
hcfmusp.citation.wos 10
hcfmusp.affiliation.country Brasil
hcfmusp.affiliation.country Venezuela


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics